Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Blackberry Flavonoid Absorption and Effects on Intestinal Bacteria

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Janet Novotny
共同編集者
National Cancer Institute (NCI)

キーワード

概要

Intestinal bacteria can metabolize unabsorbed polyphenols (plant compounds) to produce smaller molecules which may impact health. In addition, evidence suggests that this process may be affected by body fatness. This study aims to investigate absorption of blackberry polyphenols, their impact on intestinal bacteria, polyphenol metabolites formed by intestinal bacteria, and how these processes differ for obese and lean individuals. It is hypothesized that polyphenol absorption and metabolism will differ between obese and lean individuals and that differences in intestinal microbiota may play a role.

日付

最終確認済み: 06/30/2014
最初に提出された: 09/11/2013
提出された推定登録数: 09/11/2013
最初の投稿: 09/16/2013
最終更新が送信されました: 07/20/2014
最終更新日: 07/21/2014
実際の研究開始日: 08/31/2013
一次完了予定日: 03/31/2014
研究完了予定日: 03/31/2014

状態または病気

Metabolic Syndrome

介入/治療

Other: Blackberries

Other: Control

段階

-

アームグループ

介入/治療
Experimental: Control-Blackberry
Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
Experimental: Blackberry-Control
Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).

適格基準

研究の対象となる年齢 25 Years に 25 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- 25-75 years old

Exclusion Criteria:

- Use of blood-thinning medications such as Coumadin (warfarin), Dicumarol (dicumarol), or Miradon (anisindione)

- Presence of any gastrointestinal disease, metabolic disease, or malabsorption syndromes that may interfere with the study goals

- Have been pregnant during the previous 12 months, are currently pregnant or lactating, or plan to become pregnant during the study

- Type 2 diabetes requiring the use of oral antidiabetic agents or insulin

- Fasting triglycerides greater than 300 mg/dL

- Fasting glucose greater than 126 mg/dL

- History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)

- Use of prescription or over-the-counter antiobesity medications or supplements (e.g., phenylpropanolamine, ephedrine, caffeine) during and for at least 6 months prior to the start of the study or a history of a surgical intervention for obesity

- Active cardiovascular disease (such as a heart attack or procedure within the past three months or participation in a cardiac rehabilitation program within the last three months, stroke, or history/treatment for transient ischemic attacks in the past three months, or documented history of pulmonary embolus in the past six months).

- Use of any tobacco products in past 3 months

- Unwillingness to abstain from herbal supplements for two weeks prior to the study and during the study

- Known (self-reported) allergy or adverse reaction to blackberries or other study foods

- Unable or unwilling to give informed consent or communicate with study staff

- Self-report of alcohol or substance abuse within the past twelve months and/or current acute treatment or rehabilitation program for these problems (Long-term participation in Alcoholics Anonymous is not an exclusion)

- Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

結果

主な結果の測定

1. Change in fecal microbiota [0 weeks, 4 weeks]

Feces will be analyzed for bacterial typing at 0 and 4 weeks of each diet period.

二次的な結果の測定

1. Change in blackberry nutrients & metabolites [0, 30, 60, 90, 120, 150, 180, 240, 300, 360, and 420 minutes]

その他の成果対策

1. Change in gene expression [0 weeks, 4 weeks]

Gene expression in whole blood will be evaluated at the beginning and end of each diet period, through global gene expression using the Affymetrix platform. Changes in specific genes observed with global gene expression technology will be confirmed through RT-PCR.

2. Change in metabolomics [0 weeks, 4 weeks]

Blood, urine, and feces will be analyzed by a technique called metabolomics, which is a broad sampling of metabolites.

3. Change in biomarkers of cancer [0 weeks, 4 weeks]

Biomarkers of cancer risk such as oxidative stress and inflammatory markers will be analyzed at the beginning and end of each diet period.

4. Change in lipopolysaccharide [0 weeks, 4 weeks]

Lipopolysaccharide will be measured in the blood as a measure of gut leakiness.

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge